Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for physicians, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
  • Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target used to treat CLL/SLL
  • Develop treatment plans to address unique clinical challenges, based on the available evidence and recommendations outlined in the NCCN Guidelines to optimize outcomes for patients with CLL/SLL
  • Evaluate the evolving role of measurable residual disease (MRD; often referred to as minimal residual disease), allogeneic hematopoietic cell transplant, and CAR T-cell therapy
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; BeiGene; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Course summary
Available credit: 
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
Course opens: 
12/22/2022
Course expires: 
12/22/2023
Cost:
$0.00

Deborah Stephens, DO
Associate Professor, Hematology
Huntsman Cancer Center Institute
University of Utah
Salt Lake City, Utah

Jennifer Woyach, MD
Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Brian Hill, MD, PhD (slide creation)
Abbvie, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Pharmacyclics: Consultant/Advisor/Speaker

Deborah Stephens, DO
AbbVie/Genentech: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Celgene/Bristol-Myers Squibb: Consultant/Advisor/Speaker
Eli Lilly and Company: Consultant/Advisor/Speaker
Epizyme: Consultant/Advisor/Speaker
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
TG Therapeutics, Inc.: Consultant/Advisor/Speaker

Jennifer Woyach, MD
Abbvie, Inc.: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker
Loxo Oncology, Inc.: Consultant/Advisor/Speaker
NewWave BioSciences, Inc.: Consultant/Advisor/Speaker
Pharmacyclics: Consultant/Advisor/Speaker
Schrödinger, Inc.: Grant/Research Support

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 2.0 contact hours.

Pharmacists
NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-0000-22-137-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until December 22, 2023. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing